PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
These records included data from a few weeks of hospitalization while they were being evaluated and the diagnosis of TBR HAT confirmed.
- These records included data from a few weeks of hospitalization while they were being evaluated and the diagnosis of TBR HAT confirmed.
- As their conditions began to deteriorate, patients were often treated with arsenic or related compounds, sent to a Sleeping Sickness Hospital, or sent home to die with their families.
- The natural history records do not include long term outcomes data for many of the patients.
- One suramin-treated patient tested positive for HIV (only 23% tested) and 16/76 (21%) of patients tested were positive for malaria.